Publication
Article
Pharmacy Times
The practice of off-label use of prescriptionmedications occurs in approximately 1in every 5 scripts filled in the United States.This practice is potentially risky because75% of these off-label uses do not haveextensive scientific support, according tostudy results reported in the Archives ofInternal Medicine (May 8, 2006). Once theFDA approves a drug for 1 indication, physicianscan prescribe it for other uses.
For the study, the researchers determinedthe frequency of and reasons foroff-label use by looking at a 2001 surveythat examined patterns for 160 routinelyprescribed drugs from office-based physicians.That year, there were an estimated150 million off-label scripts written, or 21%of the total. Of those, 27% were for indicationssupported by scientific evidence. Yet,the remaining 73% (109 million prescriptions)had little or no evidence supportingthe use in question.
The investigators concluded that off-labeluse needs better scrutiny. Physicians, too,need to be alert to the potential positiveand negative outcomes. This type of surveillance,lead author Randall Stafford, MD,PhD, said, "would be particularly importantfor off-label uses which haven't gonethrough that initial step of being reviewedby the FDA."
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.